Ceragenix - 510k Clearance of EpiCeram®

>Ceragenix Pharmaceuticals, Inc., (OTC BB: >CGXP.OB) a biopharmaceutical company focused on infectious disease and dermatology, announced it has received 510k clearance from the FDA for its EpiCeram® Skin Barrier Emulsion to improve dry skin conditions and to relieve and manage the burning and itching associated with various dermatoses including atopic dermatitis, irritant contact dermatitis, radiation dermatitis, and other dry skin conditions. EpiCeram® is a topical, non-steroidal treatment that consists of a specific combination of lipids. The product will be available on a prescription-only basis. Ceragenix has licensed the lipid skin barrier technology from The Regents of the University of California on an exclusive basis for all prescription applications.

According to the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), more than 15 million people in the U.S. have symptoms of atopic dermatitis. Children are more commonly affected than adults, with 90 percent of acute dermatitis cases diagnosed by age five. Roughly 60 percent of infants affected continue to have one or more symptoms of atopic dermatitis into adulthood. NIAMS researchers project that U.S. health insurance companies spend more than $1 billion per year on atopic dermatitis.